- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Johnson & Johnson Innovation Catalyzes New and Exciting Science and Technology in Pharmaceutical, Medical Device, Diagnostic and Consumer Healthcare Spaces
Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheimer’s, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics for skin infections
New Long-Term Data Show INVOKANA® (canagliflozin) Lowers Blood Glucose in Older Patients with Type 2 Diabetes Inadequately Controlled on Other Therapies
Phase 3 Study Results Also Demonstrate INVOKANA® Reduces Secondary Endpoints of Body Weight and Systolic Blood Pressure
IMAAGEN Data Demonstrate that Abiraterone Acetate Plus Prednisone (5mg once daily) Lowers PSA Levels in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0-CRPC)
Phase 2 study data presented at the 50th annual meeting of the American Society of Clinical Oncology
Ibrutinib (IMBRUVICA®) RESONATET™ Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 3 data (Abstract LBA7008) featured in the official press program of the 50th annual meeting of the American Society of Clinical Oncology and simultaneously published in The New England Journal of Medicine
Ibrutinib (IMBRUVICA®) Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia
Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology